Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the previous analgesic use in real practice at the investigator's discretion.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Patients complaining of cancer pain which requires administration of long-acting opioid analgesics

• Patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics

• Patients who are deemed to need an initial minimum dose of fentanyl matrix 75 micrograms/h

• Patients who signed the informed consent form

Exclusion Criteria:

• Patients with a history of or current drug or alcohol abuse

• Childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception

• Patients who are unable to use a transdermal system due to skin disease

• Patients with history of hypersensitivity to opioid analgesics

• Patients who are not eligible for the study participation based on warnings, precautions and contraindications in the package insert of the study drug at the investigator's discretion